Want to see TSE:EBM full AI Analyst Report?
Top Page
Eastwood Bio-Medical Canada
(EBM)
Select Model
Select Model
Rating:47Neutral
Price Target:
C$2.00
▲(8.11% Upside)
Action:Reiterated
Date:10/01/26
The score is held back primarily by weak financial performance: persistent operating/net losses, deeply negative equity, and inconsistent cash generation. Technicals are a key offset, with the stock trading above major moving averages and positive momentum signals. Valuation remains constrained by the lack of profitability and no stated dividend yield.
Positive Factors
Revenue Rebound
TTM revenue growth of 309% shows a substantial rebound in demand and commercial activity after prior volatility. If sustained, this expanding base can improve operating leverage and give the company a stronger path toward future profitability.
Negative Factors
Negative Equity
TTM equity of about -$1.78M, versus -$0.29M in 2022, shows accumulated losses have materially weakened the capital base. This reduces financial flexibility, raises financing and refinancing risk, and can constrain the company's ability to absorb setbacks.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Rebound
TTM revenue growth of 309% shows a substantial rebound in demand and commercial activity after prior volatility. If sustained, this expanding base can improve operating leverage and give the company a stronger path toward future profitability.
Read all positive factors
Eastwood Bio-Medical Canada (EBM) vs. iShares MSCI Canada ETF (EWC)
Market Cap
C$130.88M
Dividend YieldN/A
Average Volume (3M)12.01K
Price to Earnings (P/E)―
Beta (1Y)0.31
Revenue Growth36.59%
EPS Growth43.33%
CountryCA
Employees3
SectorGeneral
Sector StrengthN/A
IndustryMedical - Pharmaceuticals
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding68,885,970
10 Day Avg. Volume10,357
30 Day Avg. Volume12,007
Financial Highlights & Ratios
PEG Ratio5.35
Price to Book (P/B)-29.59
Price to Sales (P/S)61.66
P/FCF Ratio2.50K
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Eastwood Bio-Medical Canada Business Overview & Revenue Model
Company Description
Eastwood Bio-Medical Canada Inc., established in Richmond, Canada, in 2010, is a company focused on the worldwide marketing and distribution of natural health products. Operating under the Eleotin brand, their offerings are available across Canada...
Eastwood Bio-Medical Canada Financial Statement Overview
Summary
Income Statement
28
Negative
Balance Sheet
18
Very Negative
Cash Flow
22
Negative
| Breakdown | TTM | Jan 2026 | Jan 2025 | Oct 2023 | Oct 2022 | Jan 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 812.12K | 782.08K | 702.08K | 867.94K | 1.30M | 981.05K |
| Gross Profit | 538.18K | 506.03K | 454.39K | 440.51K | 902.74K | 458.37K |
| EBITDA | -238.60K | -309.73K | -342.05K | -410.58K | -32.33K | -495.50K |
| Net Income | -231.56K | -332.77K | -455.87K | -546.60K | -160.58K | -611.34K |
Balance Sheet | ||||||
| Total Assets | 256.96K | 218.77K | 274.29K | 489.14K | 584.53K | 691.12K |
| Cash, Cash Equivalents and Short-Term Investments | 3.53K | 17.70K | 0.00 | 18.45K | 39.84K | 20.87K |
| Total Debt | 63.65K | 78.01K | 79.61K | 23.08K | 62.25K | 31.35K |
| Total Liabilities | 2.04M | 1.85M | 1.57M | 1.33M | 878.73K | 835.44K |
| Stockholders Equity | -1.78M | -1.63M | -1.30M | -840.80K | -294.20K | -144.32K |
Cash Flow | ||||||
| Free Cash Flow | -9.42K | 19.30K | -15.22K | -16.89K | -7.30K | -121.79K |
| Operating Cash Flow | -9.43K | 19.30K | -15.22K | -16.89K | -4.29K | -116.21K |
| Investing Cash Flow | 0.00 | 0.00 | 0.00 | 0.00 | -3.00K | -5.57K |
| Financing Cash Flow | -7.69K | -211.00 | -4.62K | -4.50K | 26.27K | 20.00K |
Eastwood Bio-Medical Canada Technical Analysis
Positive
1.85
Price Trends
1.62
Positive
1.25
Positive
1.00
Positive
Market Momentum
0.06
Positive
69.08
Neutral
75.46
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:EBM, the sentiment is Positive. The current price of 1.85 is above the 20-day moving average (MA) of 1.84, above the 50-day MA of 1.62, and above the 200-day MA of 1.00, indicating a bullish trend. The MACD of 0.06 indicates Positive momentum. The RSI at 69.08 is Neutral, neither overbought nor oversold. The STOCH value of 75.46 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TSE:EBM.
Eastwood Bio-Medical Canada Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
47 Neutral | C$130.88M | -629.03 | 13.66% | ― | 36.59% | 43.33% | |
47 Neutral | C$57.80M | -11.56 | 9999.00% | ― | -36.92% | 13.03% | |
44 Neutral | C$60.46M | -19.29 | 74.79% | ― | ― | -15.53% | |
43 Neutral | C$36.84M | -15.42 | 448.05% | ― | ― | 24.65% | |
42 Neutral | C$58.28M | -0.76 | -2099.75% | ― | -100.00% | 94.43% |
* General Sector Average
TSE:EBM
Eastwood Bio-Medical Canada
1.95
1.52
348.28%
TSE:ARCH
Arch Biopartners
0.83
-0.36
-30.25%
TSE:ADK
Diagnos
0.48
0.18
58.33%
TSE:ATLE
Willow Biosciences Inc
0.13
-0.04
-21.88%
TSE:ZYUS
ZYUS Life Sciences
0.58
-0.10
-14.71%
TSE:SONA
Sona Nanotech Inc
0.33
-0.24
-42.11%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.